ClinicalTrials.gg
CompletedNCT05908175Updated Dec 18, 2024

FES-assisted Gait Intervention in People with Spinal Cord Injury - Pilot Study

An interventional study of FES-assisted gait training in Spinal Cord Injuries, sponsored by Stichting Reade. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by Stichting Reade · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Spinal Cord Injuries with a site in Netherlands — 5 open to participants now, 6 under way, none of them phase 3. Spinal Cord Injuries · Netherlands.

Enrollment
16th of 18
5 · median 18
Started
2023
with 4 others
No phase
17 of 22
5 open now
Registered
12th of 22
by date
Lead sponsor
3 of 22
Stichting Reade

Among the 22 studies in Spinal Cord Injuries with a site in Netherlands, this one is the 16th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2023, is one of 17 with no phase, and was the 12th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

5 of the 22 studies in Spinal Cord Injuries with a site in Netherlands are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Spinal Cord Injuries with a site in Netherlands, or all of them as a file.
02

Study summary

A spinal cord injury (SCI) disrupts the communication within the nervous system, leading to limitations in sensorimotor activities such as walking. Regular use of functional electrical stimulation (FES) can result in recovery of voluntary muscle control and muscle strength. Locomotor training with FES may be a promising method to improve gait function. The primary objective of this pilot study is to assess the feasibility and safety of an FES-assisted gait training intervention. Secondary objectives are to assess the effects of an FES-assisted gait training intervention on gait function.

Read the detailed description

A spinal cord injury (SCI) disrupts the communication within the nervous system, leading to limitations in sensorimotor activities, such as walking. These limitations are associated with muscle weakness, a disturbance of the reflex activity, and the inability or difficulty to recruit muscles below the lesion. Regular use of functional electrical stimulation (FES) can result in recovery of voluntary muscle control and muscle strength. Studies that investigated the effect of locomotor training on a treadmill with functional electrical stimulation and/or body weight support (BWS) show improved function of the lower limbs. FES-assisted gait therapy may be a promising method for improving gait function in individuals with an incomplete SCI. Therefore, this study will investigate if an FES-assisted gait (with BWS) is feasible and safe. This study will also investigfate if an FES-assisted gait can improve gait function in people with an incomplete SCI.

Primary objective of this pilot study is to assess the feasibility and safety of an FES-assisted gait training intervention. The secondary objectives are to assess the effects of an FES-assisted gait training intervention on gait function.

03

Conditions studied

  • Spinal Cord Injuries
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a non-progressive incomplete SCI.
  • Have limited motor abilities in the lower extremities.
  • Be able to walk on a treadmill for 30 minutes (with body weight support).
  • Be able to perform the 10 meter walk test overground with assistive devices and/or support form the researcher/physician.
  • Have a stable medical condition.
  • Have had the SCI for at least a year.
  • Be at least 18 years of age.

Exclusion criteria

Exclusion Criteria:

  • Cardiac arrhythmias or cardiac disease;
  • Flaccid paralysis.
  • Musculoskeletal dysfunction, uncured fractures, contractures, pressure injuries, or infections that could impede the intended training;
  • A history of severe autonomic dysreflexia assessed with the 'Autonomic standards assessment';
  • Neurostimulator, pacemaker, or other device that prevents the safe use of electrical stimulation present in the body;
  • Very high sensitivity to electrical stimulation, i.e., sensitivity threshold is reached before motor responses are observed in all target muscles;
  • Insufficient mastery of the Dutch language (speaking and reading);
  • Severe cognitive or communicative disorders;
  • Being or becoming pregnant during the study period;
  • Severe psychiatric illness or disorders (at the discretion of the treating rehabilitation physician);
  • Involved in another intervention study which may have an effect on the outcome measures of the present study;
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Other
    Intervention group

    FES-assisted gait training intervention group

    Other: FES-assisted gait training

Interventions

  • OtherFES-assisted gait training

    The participants will walk with functional electrical stimulation (and possible body weight support) on a treadmill for 10 weeks, twice a week for 30 minutes.

06

What researchers measure

Primary outcomes

  1. Feasibility of the intervention

    Self-administered questionnaires about the training sessions, preceived effect, applicability of FES and the experience with walking with FES.

    Time frame: Assessed during week 11 during the post-intervention measurement.

  2. Incidence of (Serious) Adverse Events [Safety of the Intervention]

    The total number of (serious) adverse events

    Time frame: Assessed during week 1 to 10 for each FES-assisted gait training session (2x week) and in week 0, week 11 and week 21 (during the pre-, post- and follow-up measurements)

Secondary outcomes

  1. Change in average and maximum treadmill walking speed

    Average and maximum walking speed (m/s) recorded by the treadmill during each training session

    Time frame: Assessed during each FES-assisted gait training session (from week 1 until week 10, 2x a week)

  2. Change in distance

    Distance (in meters) recorded by the treadmill during each training session.

    Time frame: Assessed during each FES-assisted gait training session (from week 1 until week 10, 2x a week)

  3. Change in average overground walking speed

    Walking speed (m/s) measured by 10 meter walk test

    Time frame: Assessed before and after the 10-weeks FES-assisted gait training intervention (during week 0 and week 11)

  4. Change in muscle activity

    Surface EMG measurement during 10 meter walk test. Time of muscle activation and duration of muscle activity of the m. rectus femoris, m. vastus lateralis, m. semitendinosus, m. tibialis anterior, m. gastrocnemius medialis, m. soleus and m. peroneus longus

    Time frame: Assessed before and after the 10-weeks FES-assisted gait training intervention (during week 0 and week 11)

  5. Change in step length

    Step length left and right (cm) measured during 10 meter walk test with the interactive walkway (kinect)

    Time frame: Assessed before and after the 10-weeks FES-assisted gait training intervention (during week 0 and week 11)

  6. Change in step width

    Step width (cm) measured during 10 meter walk test with interactive walkway (kinect)

    Time frame: Assessed before and after the 10-weeks FES-assisted gait training intervention (during week 0 and week 11)

  7. Change in cadence

    Cadence (steps/min) measured during 10 meter walk test with interactive walkway (kinect)

    Time frame: Assessed before and after the 10-weeks FES-assisted gait training intervention (during week 0 and week 11)

07

Study locations

1 site
  • Stichting Reade
    Amsterdam, 1054HW, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Jun 2024, 12 months.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's 12 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2023
First posted
Jun 18, 2023
StartActual
May 10, 2023
Primary completionActual
Jun 7, 2024
CompletionActual
Jun 7, 2024
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05908175
Lead sponsor
Stichting Reade
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
May 10, 2023
Primary completion
Jun 7, 2024
Completion
Jun 7, 2024
Last update
Dec 18, 2024

Study contacts

Thomas Janssen, Prof. Dr.
principal investigator · Stichting Reade

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion